Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Emmanuelle Weiller"'
Publikováno v:
Annals of General Psychiatry, Vol 17, Iss 1, Pp 1-8 (2018)
Abstract Background Despite the availability of effective antidepressants, about half of patients with major depressive disorder (MDD) display an inadequate response to their initial treatment. A large patient survey recently reported that 29.8% of M
Externí odkaz:
https://doaj.org/article/2a0238f9b39e49d484dfe20338d90318
Publikováno v:
BMC Psychiatry, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Evidence suggests that nearly half of patients with major depressive disorder (MDD) do not achieve an adequate response to antidepressant treatments (ADTs), which impacts patients’ functioning, quality of life (QoL), and well-be
Externí odkaz:
https://doaj.org/article/7c202c48702343d99577204a309ae7dc
Autor:
Emmanuelle Weiller, Catherine Weiss, Keva Gwin, Peter Zhang, Robert D. McQuade, Ruth A Duffy, Ross A. Baker
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
The aim of this analysis was to explore the effects of brexpiprazole and aripiprazole on body weight when used as monotherapy to treat schizophrenia and as adjunctive treatment to antidepres
The aim of this analysis was to explore the effects of brexpiprazole and aripiprazole on body weight when used as monotherapy to treat schizophrenia and as adjunctive treatment to antidepres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657be1763a46e76aa7b7e52e8507616f
http://europepmc.org/articles/PMC6078484
http://europepmc.org/articles/PMC6078484
Publikováno v:
Current Medical Research and Opinion. 34:2197-2205
Objective: To analyze the effect of brexpiprazole on metabolic parameters and body weight in adults with schizophrenia, including clinically relevant sub-groups of patients, based on data from two pivotal phase 3 studies (NCT01393613; NCT01396421) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbc255a6ac7dd1871df6f8dc2ac6f59b
https://doi.org/10.1080/03007995.2018.1498779
https://doi.org/10.1080/03007995.2018.1498779
Publikováno v:
Journal of Affective Disorders. 227:103-108
Background Patients with major depressive disorder (MDD) who do not adequately respond to antidepressant treatment (ADT) may benefit from adjunctive atypical antipsychotics; however, certain agents target specific symptoms of depression and not the f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f690ff658e0038f06068d542da0f8d
https://doi.org/10.1016/j.jad.2017.09.054
https://doi.org/10.1016/j.jad.2017.09.054
Autor:
Emmanuelle Weiller, Christopher P Watling, Christopher Edge, Catherine Weiss, Mary Hobart, Maurizio Fava, Hans Eriksson
Publikováno v:
Neuropsychiatric Disease and Treatment
Objective Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10dbe03bbb426b172ae2566da853bfc5
https://doi.org/10.2147/ndt.s146840
https://doi.org/10.2147/ndt.s146840
Autor:
Emmanuelle Weiller, Peter Zhang, James Craig Nelson, Catherine Weiss, Mary Hobart, Aleksandar Skuban, Michael E. Thase
Publikováno v:
Current Psychiatry Reviews. 12:278-290
Background: Many patients with major depressive disorder (MDD) do not respond adequately to first-line antidepressant treatment (ADT). Adjunctive treatment with second-generation antipsychotics has demonstrated efficacy for patients with MDD, but is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f47bcb50a9c370276a1d9a92e361b81e
https://doi.org/10.2174/1573400512666160816095900
https://doi.org/10.2174/1573400512666160816095900
Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Autor:
Aleksandar Skuban, Michael E. Thase, Catherine Weiss, James Craig Nelson, Peter Zhang, Mary Hobart, Emmanuelle Weiller
Publikováno v:
Current Psychiatry Reviews. 12:291-301
Objective: To summarize efficacy data from two phase 2 and two phase 3 short-term, multicenter, randomized, double-blind, placebo-controlled studies of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f34de6da7f763dddb4684a370480df47
https://doi.org/10.2174/1573400512999160901094451
https://doi.org/10.2174/1573400512999160901094451
Publikováno v:
Neuropsychiatric Disease and Treatment
Michael E Thase,1 Emmanuelle Weiller,2 Peter Zhang,3 Catherine Weiss,4 Roger S McIntyre5 1Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA; 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9060ef8efada73ecb042aba0e63c8024
https://www.dovepress.com/adjunctive-brexpiprazole-in-patients-with-major-depressive-disorder-an-peer-reviewed-article-NDT
https://www.dovepress.com/adjunctive-brexpiprazole-in-patients-with-major-depressive-disorder-an-peer-reviewed-article-NDT
Autor:
Catherine Weiss, Mette Krog Josiassen, Emmanuelle Weiller, Mika Juhani Hakala, John Ouyang, Mary Hobart, Stephen R. Marder, Peter Zhang
Publikováno v:
Acta Neuropsychiatrica. 29:278-290
ObjectiveReview efficacy, safety, and tolerability of brexpiprazole in patients with schizophrenia in short- and long-term phase 3 studies.MethodsPatients experiencing a current exacerbation of schizophrenia received brexpiprazole in two fixed-dose (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a628dc903a11e0b681df92f81c5e9bb6
https://doi.org/10.1017/neu.2016.57
https://doi.org/10.1017/neu.2016.57